The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most important global academic platforms in urology.

The 2026 ASCO Genitourinary Cancers Symposium (ASCO-GU) recently concluded successfully in San Francisco, USA. As one of the most influential global academic conferences in the field of genitourinary oncology, the meeting brings together the latest research advances and evolving clinical perspectives from around the world.

The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most influential academic platforms in global urology. 

For patients with end-stage kidney disease, kidney transplantation represents a life-changing treatment that can restore quality of life and offer a “second chance.” However, transplantation success is only the beginning of a long journey. Lifelong immunosuppressive therapy—while essential for preventing rejection—also exposes recipients to a significant risk: infection.

The concept of synthetic lethality, achieved through PARP inhibitors (PARPi), has ushered in the era of precision therapy for prostate cancer. Clinical studies evaluating PARPi either as monotherapy or in combination with next-generation androgen receptor pathway inhibitors (ARPI), such as PROfound and PROpel, have already produced landmark advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

The treatment landscape for muscle-invasive bladder cancer (MIBC) is undergoing profound transformation. Although cisplatin-based neoadjuvant chemotherapy remains the traditional standard of care, the pathological complete response (pCR) rate has long remained at approximately 30%–40%, and a substantial proportion of patients cannot receive cisplatin due to factors such as renal insufficiency. Consequently, more effective preoperative treatment strategies are urgently needed.

At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), Chinese investigators once again made a strong impact on the international stage. Immunotherapy combined with targeted therapy has become the mainstream treatment paradigm for advanced renal cell carcinoma. However, key clinical questions remain unresolved worldwide, particularly how to optimize treatment strategies after immune-oncology (IO) therapy failure and how to rationally sequence or combine therapies in the era of multiple available agents.

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) has successfully concluded. As the premier annual academic event in the field of genitourinary oncology, the meeting brought together leading experts from around the world and showcased numerous cutting-edge studies and breakthroughs with the potential to reshape clinical practice.

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) was held in San Francisco, USA, from February 26 to 28, showcasing some of the most innovative scientific advances in the field and exploring future directions in the treatment of genitourinary malignancies. In recent years, research and clinical practice in urologic oncology in China have advanced rapidly. More than 70 studies led by Chinese experts and investigators were presented at the meeting. Among them, the Department of Urology at West China Hospital of Sichuan University contributed 10 studies, including six in prostate cancer, two in upper tract urothelial carcinoma, and two in renal cell carcinoma, highlighting the growing impact of Chinese research on the global stage.

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) was held in San Francisco, bringing together leading experts from around the world. As one of the most influential academic meetings in genitourinary oncology, the landmark studies presented each year at ASCO GU often directly shape the evolution of clinical practice globally.